Lundbeck’s Steve Turley (pictured right) and Actelion’s Robin Bhattacherjee (pictured left) have been appointed as Chair and Vice-Chair of the European Medicines Group (EMG).
Mr Turley, who has been elected for the 2012-2013 term of office, replaces UCB’s Matthew Speers after he stood down following his two year stewardship.
The new Chair said a priority of the Group would be “addressing the challenges faced by medicines” not appraised by NICE or a national commissioning body, which are then “subject to variations in local decision making processes about levels of access”.
Mike Sumpter, CEO of Servier Laboratories, will continue in role as Treasurer of EMG.
The EMG supports research-driven UK pharmaceutical companies globally headquartered on the continent.
Its 16 members represent a broad range of various-sized companies. Member companies currently account for more than a fifth of total medicine sales to the NHS – although the Group is eager to attract other research-driven European pharmaceutical companies.
New Vice-Chair Robin Bhattacherjee commented on the importance of having a “European Voice” here in the UK. “Supply of medicines is one example and how value of medicines could be determined in the UK, and the implications of this on pan-European pricing, will be a key issue over the next couple of years,” he said.
Share this article: